Update shared on23 Aug 2025
Fair value Increased 1k%Driven by a substantial improvement in both the future P/E multiple and net profit margin, Q-linea's consensus analyst price target has surged from SEK5.54 to SEK80.00.
What's in the News
- Q-linea and BLASTID demonstrated a successful proof-of-concept for rapid direct-from-whole-blood organism isolation, enrichment, and phenotypic antibiotic susceptibility testing, delivering clinically actionable results in less than 8 hours.
- Initial results focused on the ESKAPE bacterial panel, using BLASTID's SPLENDID platform and Q-linea’s ASTar instrument, and were presented at the ADLM2025 Conference in Chicago.
- The research received partial funding from the United States Government, ARPA-H.
- Q-linea AB announced a 1:1000 stock split or significant stock dividend effective July 14.
Valuation Changes
Summary of Valuation Changes for Q-linea
- The Consensus Analyst Price Target has significantly risen from SEK5.54 to SEK80.00.
- The Future P/E for Q-linea has significantly risen from 2.01x to 23.01x.
- The Net Profit Margin for Q-linea has significantly risen from 8.06% to 10.19%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.